BridgeBio Pharma
BBIO • NASDAQ
BridgeBio Pharma is a biotechnology company in the healthcare sector trading on NASDAQ, led by CEO Neil Kumar, with a market cap of $13.5B.
CEONeil Kumar
Next Earnings
Upcoming earnings announcement for BridgeBio Pharma
Date
Tuesday, April 28, 2026 (in 4 weeks)
Timing
After Market Close (4:00 PM New York)
Fiscal Period
Q1 2026
EPS Estimate
-$0.68
Revenue Estimate
$178.7M
Earnings History
Past 12 earnings reports for BridgeBio Pharma
| Date | Period | EPS | EPS Surprise | Revenue | Rev. Surprise | Filing |
|---|---|---|---|---|---|---|
| Feb 24, 2026 | Q4 2025 | -$1.00Est: -$0.67 | -49.3% | $154.2MEst: $149.5M | +3.2% |  10-K |
| Oct 29, 2025 | Q3 2025 | -$0.95Est: -$0.82 | -15.9% | $120.7MEst: $105.8M | +14.1% | 10-Q |
| Aug 5, 2025 | Q2 2025 | -$0.95Est: -$0.68 | -39.7% | $110.6MEst: $95.7M | +15.5% | 10-Q |
| Apr 29, 2025 | Q1 2025 | -$0.88Est: -$1.00 | +12.0% | $116.6MEst: $57.7M | +102.0% | 10-Q |
| Feb 20, 2025 | Q4 2024 | -$1.40Est: -$1.09 | -28.4% | $5.9MEst: $4.0M | +45.6% | 10-K |
| Nov 12, 2024 | Q3 2024 | -$0.86Est: -$0.98 | +12.2% | $2.7MEst: $3.8M | -27.3% | 10-Q |
| Aug 1, 2024 | Q2 2024 | -$1.06Est: -$1.04 | -1.9% | $2.2MEst: $3.6M | -39.3% | 10-Q |
| May 2, 2024 | Q1 2024 | -$0.20Est: -$0.89 | +77.5% | $211.1MEst: $14.0M | +1404.8% | 10-Q |
| Feb 22, 2024 | Q4 2023 | -$0.96Est: -$0.91 | -5.5% | $1.7MEst: $6.2M | -72.0% | 10-K |
| Nov 2, 2023 | Q3 2023 | -$1.08Est: -$0.81 | -33.3% | $4.1MEst: $4.3M | -4.0% | — |
| Aug 3, 2023 | Q2 2023 | -$0.98Est: -$0.83 | -18.1% | $1.6MEst: $3.0M | -45.1% | 10-Q |
| May 4, 2023 | Q1 2023 | -$0.92Est: -$0.83 | -10.8% | $1.8MEst: $3.4M | -45.8% | — |